CardioVascular BioTherapeutics’ lead heart disease medication has been granted Phase II testing permission after solid results were found in Phase I trials. Phase II catheter and placebo tests promise to move this quality of life medication one step closer to final approvals.
The bioscience company is involved in developing drug treatments designed to help people with critical heart disease issues. It is also involved in developing a drug treatment that helps with the healing process of wounds and lesions associated with diabetes. As with any bioscience company, getting the drug treatments through the testing and approvals process is the main struggle, past developing the drug.
CardioVascular BioTherapeutics is well along the critical path of testing and approvals having completed the Phase I portion of approvals and receiving permission for Phase II catheter and placebo tests, with regards to its heart disease drug. Phase I testing showed a marked improvement in critical care heart disease patients that had little or no recourse except to try an experimental medication.
Although there may be similarities to other heart disease medications, the company’s medication works to help grow new blood vessel systems around the affected areas. As the new blood vessel systems are formed increased blood flow results. Increased blood flow leads to increased oxygen and nutrient capacity and better opportunity for quality of life where once there was little hope.
CardioVascular BioTherapeutics’ diabetes wound care medication is currently in its Phase I testing process and showing positive indicators. The sheer number of diabetic patients that could make use of this possible wound care medication makes taking a strong look at the company compelling.
The company currently has a series of other drug trials in the pipeline at various stages of development and approvals. Given the nature of the approvals process the future of these drugs is unknown. If, however, current drug testing of current products is an indication, a solid potential exists for this company.
Let us hear your thoughts below: